Analyses

Doctor Evidence (DRE) has developed state-of-the-art technology designed specifically to identify, configure, and analyze scientific and healthcare related data from published and grey literature, regulatory documents, drug labels, meeting abstracts, systematic reviews, and clinical guidelines. DRE’s team of experienced and highly trained research specialists are led by methodologists educated at leading evidence-based medicine centers. DRE’s proprietary Digital Outcome Conversion (DOC) process is used to extract data from a set of full-text articles, which are then organized into highly structured data sets. This extracted data can then be used to conduct powerful evidence-based medicine syntheses and statistical analyses.

DOC-Search

Clinical Program Analytics

DRE works with clinical development scientists to help formulate research programs based on target product profiles that incorporate a review of available literature. Analytics include identification of gaps and comparative evaluation of relevant efficacy and safety endpoints for trial planning and reporting. This literature base is expanded and refined throughout the clinical development and product lifecycle to keep pace with appropriate modifications that cover market access and life cycle management.

Indirect Treatment Comparisons/Network Meta-Analyses

DRE statisticians have considerable experience in advanced statistical approaches to compare all competing interventions through indirect comparisons, which are often required due to an absence of direct (head-to-head) comparisons for most comparative effectiveness research questions. The DRE team is expert at designing robust statistical analysis plans, conducting feasibility assessments, and ultimately running indirect treatment comparisons/network meta-analyses (NMAs). Depending on the results of the feasibility assessment, frequentist and/or Bayesian frameworks can be applied that meet the requirements of health technology assessment in Australia, Canada, Europe, and the U.S.

In situations when even more advanced methods are required (e.g., when treatment effect modifiers are identified), DRE will work with partners to acquire and use individual patient data to conduct population-adjusted treatment comparisons (i.e., matching-adjusted indirect comparisons [MAIC] and simulated treatment comparisons [STC]). In other situations, approaches such as meta-regression or multivariate models can be applied in the context of NMA.

DOC Data
DOC Label

Economic and PRO Assessments

As well as synthesizing comparative effectiveness research, DRE undertakes assessment of economic and patient-reported analyses from clinical trials and observational studies, and primary economic and comparative analyses. These reviews provide qualitative appraisals of the completeness of the analyses, consistency across studies, and uniformity of results. Gaps in analyses and findings for both economic and patient-reported outcome (PRO) instruments are provided, as well as assessment of quantitative evaluations. DRE considers model development and assesses appropriateness and completeness of evaluation.

DRE also conducts economic analyses, based on aggregate level data from publications, using cost inputs from external standard sources. For patient-reported outcomes and other humanistic measures, comparative analyses across clinical and observational studies are performed.

Medical Writing & Communication

DRE works with clinical development scientists to help formulate research programs based on target product profiles that incorporate a review of available literature. Analytics include identification of gaps and comparative evaluation of relevant efficacy and safety endpoints for trial planning and reporting. This literature base is expanded and refined throughout the clinical development and product lifecycle to keep pace with appropriate modifications that cover market access and life cycle management.

DOC TRACK
DOC Label

Scientific Publications

DRE specializes in the development and dissemination of secondary research findings through engaging abstracts, posters, presentations, and full manuscripts. Using the analyses generated by DRE’s products and services, DRE support client’s high impact publication strategy, development, and submission to leading journals and scientific congresses. DRE's software delivers content for industry-leading systematic review and scientific publications, including presentations and posters for evidence-based medicine (EBM) conferences.

DRE maintains a comprehensive network of key opinion leaders and academic organizations, including leading U.S. medical societies (e.g., American College of Chest Physicians, American Heart Association, American Society of Clinical Oncology), McMaster University, and U.S. Evidence-based Practice Centers (e.g., Brown University, Oregon Health & Science University). DRE’s leading author and publication partners span the globe in all key areas, including diagnosis, treatment, epidemiology, risk factors, humanistic burden, and economic analysis.